AbbVie pens $2B+ next-gen psychedelic pact with Gilgamesh
14 May 2024 //
FIERCE BIOTECH
AbbVie, Gilgamesh Collaborate On Next-Gen Psychiatric Therapies
13 May 2024 //
PR NEWSWIRE
Gilgamesh Initiates GM-1020 Phase 2a In Depression
01 May 2024 //
PR NEWSWIRE
Gilgamesh Pharma Awarded $14 Million National Institute on Drug Abuse Grant
14 Mar 2024 //
PR NEWSWIRE
Gilgamesh Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
21 Sep 2023 //
PR NEWSWIRE